ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMR01

Hepatocyte FOXA3 in Alcohol-Associated Liver Disease

Active
Institution
University of Arizona, AZ
Principal investigator
Yanqiao Zhang
Funding
$639K
Duration
2025–2030
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary Project Summary: Alcohol-associated liver disease (ALD) is the most prevalent type of chronic liver disease worldwide. ALD represents a spectrum of liver disorders resulting from alcohol use, ranging from alcohol- associated hepatic steatosis (i.e., alcoholic fatty liver) to more advanced forms, including alcohol-associated steatohepatitis (ASH)/hepatitis (AH) and cirrhosis (AC). Alcohol-associated hepatic steatosis is the result of the earliest response of the liver to alcohol abuse. So far, the mechanism underlying the pathogenesis of ALD remains to be fully understood. There are also limited options for the treatment of ALD. Our preliminary study shows that hepatic forkhead box A3 (FOXA3), a member of the winged-helix transcription factors, is reduced in patients or mice with ALD. In this project, we will investigate the role of hepatic FOXA3 in the development and progression of ALD. We will also characterize the underlying mechanisms. Gain- and loss-of-function approaches and state-of-the-art techniques will be used to investigate whether hepatic FOXA3 is a key player in the pathogenesis of ALD.

LOADING MOONBASE SCORE

R01Hepatobiliary Pathophysiology Study Section[HBPP]NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMhepaticliver diseasehepatic steatosisliversteatosisalcohol-associatedalcohol-associated liverald

Questions for University of Arizona

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.